Edition:
United States

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

88.74EUR
12:35pm EDT
Change (% chg)

€1.92 (+2.21%)
Prev Close
€86.82
Open
€87.46
Day's High
€88.92
Day's Low
€86.88
Volume
342,470
Avg. Vol
417,022
52-wk High
€105.35
52-wk Low
€70.64

Select another date:

Fri, Feb 22 2019

BRIEF-Galapagos FY Revenue Up At 317.8 Million Euros

* SAID ON THURSDAY FY REVENUE EUR 317.8 MLN VS EUR 155.9 MLN YR AGO

BRIEF-Galapagos And Fibrocor Sign Partnership Focusing On Fibrosis

* SAID ON FRIDAY FIBROCOR THERAPEUTICS L.P. AND GALAPAGOS SIGN PARTNERSHIP FOCUSING ON FIBROSIS

Rheinmetall says in talks to buy stake in rival Krauss-Maffei

FRANKFURT Rheinmetall on Monday said it was in talks about buying a stake in rival KMW and Nexter Defense Systems N.V, sending shares in the defense company sharply higher.

Rheinmetall says in talks to buy stake in rival Krauss-Maffei

FRANKFURT, Nov 26 Rheinmetall on Monday said it was in talks about buying a stake in rival KMW and Nexter Defense Systems N.V, sending shares in the defense company sharply higher.

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON FRIDAY A SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES

BRIEF-Galapagos Reports Top-line Interim Results Of FALCON Trial Part 1 In CF

* REPORTED ON WEDNESDAY TOPLINE INTERIM RESULTS OF FALCON TRIAL PART 1 IN CF

BRIEF-Galapagos 9-Month Revenue Rises To 205.1 Million Euros

* REPORTED ON WEDNESDAY 9-MONTH GROUP REVENUES INCREASED BY EUR 98.7 MILLION TO EUR 205.1 MILLION

BRIEF-Galapagos Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis

* REPORTED TOGETHER WITH GILEAD SCIENCES ON SUNDAY PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS

BRIEF-Galapagos: Capital Increase Of EUR 2.0 Million

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES

Select another date: